The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Official Title: Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma
Study ID: NCT01007448
Brief Summary: This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Alabama at Birmingham, Birmingham, Alabama, United States
Florida Academic Dermatology Centers, Miami, Florida, United States
Emory University, Atlanta, Georgia, United States
Rush University, Chicago, Illinois, United States
Tulane, New Orleans, Louisiana, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Minnesota Medical School, Minneapolis, Minnesota, United States
Washington University, Saint Louis, Missouri, United States
University of Rochester, Rochester, New York, United States
Duke University, Durham, North Carolina, United States
Wake Forest University Health, Winston-Salem, North Carolina, United States
University Hospitals-Case Medical Center, Cleveland, Ohio, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Vanderbilt, Nashville, Tennessee, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute At the University of Utah, Salt Lake City, Utah, United States
Name: Mandeep Kaur, MD
Affiliation: Valeant Pharmaceutical NA
Role: STUDY_DIRECTOR